Once-Weekly Semaglutide in Adolescents with Obesity.

BACKGROUND: A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking. METHODS: In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention. The primary end point was the percentage change in BMI from baseline to week 68; the secondary confirmatory end point was weight loss of at least 5% at week 68. RESULTS: A total of 201 participants underwent randomization, and 180 (90%) completed treatment. All but one of the participants had obesity. The mean change in BMI from baseline to week 68 was -16.1% with semaglutide and 0.6% with placebo (estimated difference, -16.7 percentage points; 95% confidence interval [CI], -20.3 to -13.2; P<0.001). At week 68, a total of 95 of 131 participants (73%) in the semaglutide group had weight loss of 5% or more, as compared with 11 of 62 participants (18%) in the placebo group (estimated odds ratio, 14.0; 95% CI, 6.3 to 31.0; P<0.001). Reductions in body weight and improvement with respect to cardiometabolic risk factors (waist circumference and levels of glycated hemoglobin, lipids [except high-density lipoprotein cholesterol], and alanine aminotransferase) were greater with semaglutide than with placebo. The incidence of gastrointestinal adverse events was greater with semaglutide than with placebo (62% vs. 42%). Five participants (4%) in the semaglutide group and no participants in the placebo group had cholelithiasis. Serious adverse events were reported in 15 of 133 participants (11%) in the semaglutide group and in 6 of 67 participants (9%) in the placebo group. CONCLUSIONS: Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone. (Funded by Novo Nordisk; STEP TEENS ClinicalTrials.gov number, NCT04102189.).

Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.

BACKGROUND: The incidence of type 2 diabetes mellitus is increasing among youths. Once-weekly treatment with dulaglutide, a glucagon-like peptide-1 receptor agonist, may have efficacy with regard to glycemic control in youths with type 2 diabetes. METHODS: In a double-blind, placebo-controlled, 26-week trial, we randomly assigned participants (10 to <18 years of age; body-mass index [BMI], >85th percentile) being treated with lifestyle modifications alone or with metformin, with or without basal insulin, in a 1:1:1 ratio to receive once-weekly subcutaneous injections of placebo, dulaglutide at a dose of 0.75 mg, or dulaglutide at a dose of 1.5 mg. Participants were then included in a 26-week open-label extension study in which those who had received placebo began receiving dulaglutide at a weekly dose of 0.75 mg. The primary end point was the change from baseline in the glycated hemoglobin level at 26 weeks. Secondary end points included a glycated hemoglobin level of less than 7.0% and changes from baseline in the fasting glucose concentration and BMI. Safety was also assessed. RESULTS: A total of 154 participants underwent randomization. At 26 weeks, the mean glycated hemoglobin level had increased in the placebo group (0.6 percentage points) and had decreased in the dulaglutide groups (-0.6 percentage points in the 0.75-mg group and -0.9 percentage points in the 1.5-mg group, P<0.001 for both comparisons vs. placebo). At 26 weeks, a higher percentage of participants in the pooled dulaglutide groups than in the placebo group had a glycated hemoglobin level of less than 7.0% (51% vs. 14%, P<0.001). The fasting glucose concentration increased in the placebo group (17.1 mg per deciliter) and decreased in the pooled dulaglutide groups (-18.9 mg per deciliter, P<0.001), and there were no between-group differences in the change in BMI. The incidence of gastrointestinal adverse events was higher with dulaglutide therapy than with placebo. The safety profile of dulaglutide was consistent with that reported in adults. CONCLUSIONS: Treatment with dulaglutide at a once-weekly dose of 0.75 mg or 1.5 mg was superior to placebo in improving glycemic control through 26 weeks among youths with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI. (Funded by Eli Lilly; AWARD-PEDS ClinicalTrials.gov number, NCT02963766.).

A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.

OBJECTIVE: The aim of this study was to investigate the pharmacokinetic, pharmacodynamic and safety profile of the glucagon-like peptide-1 receptor agonist, lixisenatide, for the treatment of type 2 diabetes (T2D) in pediatric individuals. MATERIALS AND METHODS: In this Phase 1, multicenter, randomized, double-blind, placebo-controlled, parallel-group, ascending repeated dose study (NCT02803918), participants aged ≥10 and < 18 years were randomized 3:1 to receive once-daily lixisenatide in 2-week increments of 5, 10, and 20 µg (n = 18) or placebo (n = 5) for 6 weeks. RESULTS: Mean lixisenatide concentrations generally increased with increasing doses irrespective of anti-drug antibody (ADA) status; however, mean lixisenatide concentrations and inter-subject variability were higher for participants with positive ADA status. Improvements in fasting plasma glucose, post-prandial glucose, AUC0-4.5 , HbA1c , and body weight were observed with lixisenatide. Overall, the safety profile was consistent with the known profile in adults, with no unexpected side effects and no treatment-emergent adverse events resulting in death or discontinuation. The most common events in the lixisenatide group were vomiting (11.1%) and nausea (11.1%). No symptomatic hypoglycemia was reported in either group. No clinically significant hematologic, biochemical or vital sign abnormalities were observed. CONCLUSIONS: Mean lixisenatide concentrations generally increased with increasing dose, irrespective of ADA status. Lixisenatide was associated with improved glycemic control and a trend in body weight reduction compared with placebo. The safety and tolerability profile of repeated lixisenatide doses of up to 20 µg per day in children and adolescents with T2D was reflective of the established safety profile of lixisenatide in adults.

Country-Specific Prevalence and Incidence of Youth-Onset Type 2 Diabetes: A Narrative Literature Review.

BACKGROUND: With increased awareness of type 2 diabetes (T2D) in children and adolescents, an overview of country-specific differences in epidemiology data is needed to develop a global picture of the disease development. SUMMARY: This study examined country-specific prevalence and incidence data of youth-onset T2D published between 2008 and 2019, and searched for national guidelines to expand the understanding of country-specific similarities and differences. Of the 1,190 articles and 17 congress abstracts identified, 58 were included in this review. Our search found the highest reported prevalence rates of youth-onset T2D in China (520 cases/100,000 people) and the USA (212 cases/100,000) and lowest in Denmark (0.6 cases/100,000) and Ireland (1.2 cases/100,000). However, the highest incidence rates were reported in Taiwan (63 cases/100,000) and the UK (33.2 cases/100,000), with the lowest in Fiji (0.43 cases/100,000) and Austria (0.6 cases/100,000). These differences in epidemiology data may be partly explained by variations in the diagnostic criteria used within studies, screening recommendations within national guidelines and race/ethnicity within countries. Key Messages: Our study suggests that published country-specific epidemiology data for youth-onset T2D are varied and scant, and often with reporting inconsistencies. Finding optimal diagnostic criteria and screening strategies for this disease should be of high interest to every country. TRIAL REGISTRATION: Not applicable.

A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.

BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56. RESULTS: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment. CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).

Recommendations for improving clinical trial design to facilitate the study of youth-onset type 2 diabetes.

BACKGROUND: The prevalence of type 2 diabetes is increasing in youths and differs from adult-onset type 2 diabetes in its characteristics and progression. Currently, only two drugs are approved for youth-onset type 2 diabetes and many patients are not meeting glycemic targets. Clearly, there is an urgent need to complete clinical trials in youths with type 2 diabetes to increase the therapeutic choice for these patients. However, factors such as limited patient numbers, unwillingness of patients to participate in trials, failure to meet strict inclusion and exclusion criteria, and poor clinic attendance have limited the size and number of trials in this complicated patient demographic. RECOMMENDATIONS: This is a narrative opinion piece on the design of clinical trials in youth-onset type 2 diabetes prepared by researchers who undertake this type of study in different countries. The review addresses possible ways to enhance trial designs in youth-onset type 2 diabetes to meet regulatory requirements, while minimizing the barriers to patients' participation. The definition of adolescence, recruitment of sufficient patient numbers, increasing flexibility in selection criteria, improving convenience of trial visits, requirements of a control group, possible endpoints, and trial compliance are all considered. The authors recommend allowing extrapolation from adult data, using multiple interventional arms within future trials, broadening inclusion criteria, and focusing on endpoints beyond glucose control, among others, in order to improve the successful completion of more trials in this population. CONCLUSIONS: Improvements in trial design will enable better recruitment and retention and thereby more evidence for treatment outcomes for youth-onset type 2 diabetes.

Youth-Onset Type 2 Diabetes Manifestations in other Specialties: Its Many Disguises.

BACKGROUND: Youth-onset type 2 diabetes (T2D) is increasing in many countries, creating large personal and societal burdens. While many primary health-care professionals (HCPs) are aware of the classic symptoms of T2D, there are several other manifestations that could indicate its presence. SUMMARY: This narrative review summarizes information on these symptoms and indicators, focusing on those less well known. The classic symptoms and comorbidities include frequent urination, excessive thirst, metabolic syndrome, and obesity. In addition to these, the presence of dermatological (e.g., acanthosis nigricans, granuloma annulare, necrobiosis lipoidica diabeticorum, and scleredema), gynecological (e.g., polycystic ovary syndrome, oligomenorrhea, and vulvovaginitis), hepatological (e.g., nonalcoholic fatty liver disease), and psychiatric diseases (e.g., psychosis, depression, and autism) could indicate that a patient has T2D or is at increased risk of T2D. Other less well-known indicators include abnormal blood tests (e.g., oxidized lipids, inflammation markers, hepatokines, and adipokines), prescriptions for antipsychotic medications or statins, and disrupted sleep patterns. Key Message: Due to the diversity of T2D manifestations in young people, primary HCPs need to remain alert to its possible presence.

Liraglutide in Children and Adolescents with Type 2 Diabetes.

BACKGROUND: Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown. METHODS: Patients who were 10 to less than 17 years of age were randomly assigned, in a 1:1 ratio, to receive subcutaneous liraglutide (up to 1.8 mg per day) or placebo for a 26-week double-blind period, followed by a 26-week open-label extension period. Inclusion criteria were a body-mass index greater than the 85th percentile and a glycated hemoglobin level between 7.0 and 11.0% if the patients were being treated with diet and exercise alone or between 6.5 and 11.0% if they were being treated with metformin (with or without insulin). All the patients received metformin during the trial. The primary end point was the change from baseline in the glycated hemoglobin level after 26 weeks. Secondary end points included the change in fasting plasma glucose level. Safety was assessed throughout the course of the trial. RESULTS: Of 135 patients who underwent randomization, 134 received at least one dose of liraglutide (66 patients) or placebo (68 patients). Demographic characteristics were similar in the two groups (mean age, 14.6 years). At the 26-week analysis of the primary efficacy end point, the mean glycated hemoglobin level had decreased by 0.64 percentage points with liraglutide and increased by 0.42 percentage points with placebo, for an estimated treatment difference of -1.06 percentage points (P<0.001); the difference increased to -1.30 percentage points by 52 weeks. The fasting plasma glucose level had decreased at both time points in the liraglutide group but had increased in the placebo group. The number of patients who reported adverse events was similar in the two groups (56 [84.8%] with liraglutide and 55 [80.9%] with placebo), but the overall rates of adverse events and gastrointestinal adverse events were higher with liraglutide. CONCLUSIONS: In children and adolescents with type 2 diabetes, liraglutide, at a dose of up to 1.8 mg per day (added to metformin, with or without basal insulin), was efficacious in improving glycemic control over 52 weeks. This efficacy came at the cost of an increased frequency of gastrointestinal adverse events. (Funded by Novo Nordisk; Ellipse ClinicalTrials.gov number, NCT01541215.).

A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2).

There are limited studies evaluating the safety and efficacy of treatments in young people with type 2 diabetes (T2D). This study compared the efficacy and safety of insulin detemir versus neutral protamine Hagedorn (NPH) insulin, both in combination with metformin and lifestyle intervention, in children and adolescents with T2D. This randomized, open-label, phase 3 trial recruited patients (n = 42) aged 10-17 years diagnosed with T2D already receiving metformin ± other oral antidiabetic drugs ± basal insulin. Patients were randomized (1:1) to receive either insulin detemir or NPH insulin, both with the maximum tolerated dose of metformin, and lifestyle intervention, over 26 weeks. Enrollment terminated prematurely after 17 months due to a very slow recruitment rate (12% of the target met). After 26 weeks, the observed mean HbA1c value had decreased by 0.61% points in the insulin detemir group vs. 0.84% points in the NPH insulin group. The rate of symptomatic blood glucose-confirmed hypoglycemic episodes was 0.4 episodes/patient-year of exposure (PYE) for insulin detemir vs. 1.1 episodes/PYE for NPH insulin. CONCLUSION: No safety issues were revealed with either basal insulin. Due to the low number of patients recruited, no efficacy conclusions could be drawn. ClinicalTrials.gov identifier: NCT02131272. What is known: • There is a growing worldwide epidemic of type 2 diabetes in children and adolescents. • There is a lack of research and limited treatment options currently available in this population. What is new: • No safety issues with insulin detemir or neutral protamine Hagedorn insulin in children and adolescents with type 2 diabetes were observed. • Improving clinical trial recruitment, along with providing early, efficacious, and safe treatment options, in this population is critical.

[Hyperinsulinemia and insulin resistance in children]. / Hiperinsulinemia y resistencia insulínica en niños de dos escuelas públicas de Oaxaca, México.

BACKGROUND: Obesity during childhood is a risk factor for developing cardiovascular diseases during adulthood. AIM: To measure insulin and glucose levels and parameters of insulin resistance in obese, overweight and normal weight Mexican children. MATERIAL AND METHODS: Comparative study of 21 obese children with a body mass index (BMI) over percentile 95, aged 10 ± 1 years (10 males), 14 children aged 10 ± 2 (7 males) with a BMI between percentiles 85 and 94 and 16 children aged 9 ± 2 years (3 males) with a body mass index between percentiles 10 and 84. Body weight, blood pressure and waist circumference were measured and a blood sample was obtained to measure fasting glucose and insulin levels. Homeostasis model of insulin resistance (HOMA) and quantitative insulin sensitivity check index (QUICKI) were calculated. RESULTS: Among obese, overweight and normal weight children, insulin levels were 14.9 (95% CI 10.90-18.99), 7.20 (CI 5.12-9.28) and 4.73 (CI 95% 1.92-7.53) uU/ml, respectively. The figures for HOMA were 3.16 (95% CI 2.20-4.12), 1.49 (95% CI 1.03-1.94) and 0.97 (95% CI 0.35-1.60), respectively. The figures for QUICKI were 0.331 (95% CI 0.319-0.343), 0.371 (95% CI 0.349-0.393) and 0.419 (95% CI 0.391-0.446), respectively. Compared to their normal weight counterparts, the risk of obese children and those with a waist circumference over percentile 90 of having a HOMA over 3.16 was 17 and 10 times higher, respectively. BMI correlated better than waist circumference with insulin levels. CONCLUSIONS: Obese children have higher levels of insulin resistance than their normal weight counterparts.

Hiperinsulinemia y resistencia insulínica en niños de dos escuelas públicas de Oaxaca, México / Hyperinsulinemia and insulin resistance in children

Background: Obesity during childhood is a risk factor for developing cardiovascular diseases during adulthood. Aim: To measure insulin and glucose levels and parameters of insulin resistance in obese, overweight and normal weight Mexican children. Material and Methods: Comparative study of 21 obese children with a body mass index (BMI) over percentile 95, aged 10 ± 1 years (10 males), 14 children aged 10 ± 2 (7 males) with a BMI between percentiles 85 and 94 and 16 children aged 9 ± 2 years (3 males) with a body mass index between percentiles 10 and 84. Body weight, blood pressure and waist circumference were measured and a blood sample was obtained to measure fasting glucose and insulin levels. Homeostasis model of insulin resistance (HOMA) and quantitative insulin sensitivity check index (QUICKI) were calculated. Results: Among obese, overweight and normal weight children, insulin levels were 14.9 (95% CI 10.90-18.99), 7.20 (CI 5.12-9.28) and 4.73 (CI 95% 1.92-7.53) uU/ml, respectively. The figures for HOMA were 3.16 (95% CI 2.20-4.12), 1.49 (95% CI 1.03-1.94) and 0.97 (95% CI 0.35-1.60), respectively. The figures for QUICKI were 0.331 (95% CI 0.319-0.343), 0.371 (95% CI 0.349-0.393) and 0.419 (95% CI 0.391-0.446), respectively. Compared to their normal weight counterparts, the risk of obese children and those with a waist circumference over percentile 90 of having a HOMA over 3.16 was 17 and 10 times higher, respectively. BMI correlated better than waist circumference with insulin levels. Conclusions: Obese children have higher levels of insulin resistance than their normal weight counterparts.

¿Es la obesidad un problema médico individual y social? Políticas públicas que se requieren para su prevención / Is obesity an individual social medical problem? Public policies for prevention

Existe abundante información científica que establece una relación entre dieta, ejercicio y enfermedades crónicas y degenerativas. Para prevenir el sobrepeso y la obesidad se requieren intervenciones en un contexto ecológico, en el que participan de manera coordinada los sectores sociales con el propósito de promover cambios en las formas de alimentación y ejercicio de las familias. Se requiere sensibilizar a la sociedad de los riesgos para la salud que conlleva cursar con sobrepeso u obesidad y de la importancia que tiene transformar los ambientes obesogénicos en que actualmente viven los niños. Se menciona la Encuesta Nacional de Salud y Nutrición (ENSANUT) 2006, como herramienta para el diseño de políticas públicas para prevenir este problema, pensando en modificar el entorno comunitario. Las políticas públicas deben propiciar que los niños hereden de sus padres buenos hábitos de alimentación y ejercicio, y buscar que la escuela se transforme en un ambiente saludable. Aunque hasta ahora ningún país tiene bajo control esta epidemia, hay esfuerzos alentadores en países como Alemania, Gran Bretaña, España y Chile en los que están participando todos los sectores sociales. En México, se identifican esfuerzos como la elaboración e implementación de los lineamientos sobre el consumo de bebidas saludables, en la necesidad de realizar cambios sustanciales en las escuelas primarias y en regular la publicidad de alimentos y bebidas dirigidas a los niños. Se menciona la estrategia de la Organización Mundial de la Salud sobre régimen alimentario, actividad física y salud, la cual involucra a todos los sectores sociales, como la pauta para realizar cambios socialmente trascendentes en las formas de alimentación y ejercicio. Se espera que siguiendo estas estrategias, bajo la coordinación de la Secretaría de Salud, que reconoce la importancia de la prevención, y al mismo tiempo con la participación de otros sectores gubernamentales y privados, será posible revertir la tendencia del sobrepeso y la obesidad.

Scientific information is available on the relationship between diet, physical activity and chronic-degenerative diseases. To prevent overweight and obesity in childhood, coordinated interventions including private and government sectors are required in an ecological context. It is necessary to transform obesogenic environments where children live, as well as to change their dietary habits and physical activity. At present, in many families the intake of simple sugars and saturated lipids is high, whereas fruits and vegetables are much less included in the diet. On the other hand, sedentarism and obesity have become a civilization symbol for society, and very few are aware of obesity risks and consequences on human health. The ENSANUT 2006, a national survey on nutrition and health, it is proposed as a tool to design public health policies to prevent obesity by modifying, when possible, community environment, and by transforming the unhealthy atmosphere of school into a healthy one. Healthful life styles must be taught and inherited from parents to their children. No country has under control this epidemic; however, there is a good expectative from experiences of countries such as Germany, Great Britain, Spain and Chile. The importance to put into practice the guidance system for healthy beverage consumption, especially in schools, and to regulate food and beverage advertising in mass media is highlighted for Mexico. The WHO global strategy on diet, physical activity and health is suggested as the guide to be adopted by the Mexican Health Ministry to perform important changes in dietary and physical activity, and to include all social actors to prevent overweight and obesity.

Recomendaciones de la Sociedad Mexicana de Endocrinología Pediátrica, A. C., para el uso de hormona de crecimiento en niños y adolescentes / Mexican society for pediatric endocrinology's recommendations for the use of human biosynthetic growth hormone in children and adolescents

El objetivo del presente trabajo es señalar consideraciones puntuales que permitan: a) recordar los mecanismos básicos de la acción de la hormona de crecimiento; b) establecer la sospecha diagnóstica de deficiencia de hormona de crecimiento; c) evaluar la utilidad de diferentes estudios de laboratorio para confirmar su existencia; d) conocer las características físicas y químicas de los diferentes productos comerciales; e) preparar y utilizar los diferentes productos comerciales para asegurar su eficacia; f) determinar los objetivos generales del tratamiento con hormona de crecimiento; g) verificar las indicaciones formales para el uso de hormona de crecimiento; h) administrar la dosis adecuada con un horario y periodicidad óptimos; i) evaluar los parámetros de eficacia de la hormona de crecimiento; j) identificar los factores que modifican la acción de la hormona de crecimiento, k) reconocer y vigilar los parámetros de seguridad durante el tratamiento con hormona de crecimiento; l) definir el momento en que debe terminar el tratamiento con hormona de crecimiento.

The aim of this paper is to present consensus guidelines for the diagnosis and treatment of children and adolescents with growth hormone deficiency, and to alert on several crucial points regarding the use of human biosynthetic growth hormone: a) the mechanism of action of natural human growth hormone; b) how to establish clinical suspicious of growth hormone deficiency; c) utility of different biochemical studies to confirm growth hormone deficiency; d) physical and chemical characteristics of the commercial kits of growth hormone; e) how to prepare and use the growth hormone kits to ensure their efficacy; f) general objectives of growth hormone treatment; g) formal indications for the use of human growth hormone; h) define dose, time and periodicity during treatment; i) efficacy parameters of growth hormone treatment; j) factors that modify the efficacy of growth hormone treatment; k) safety parameters during growth hormone treatment; l) when, how and in who stop the treatment with growth hormone.

Anillo del cromosoma 18 en un lactante con cariotipo 46, XY/46, XY, r(18), hijo de madre con mosaicismo para el anillo cromosómico / An [46,XY/46 XY,r(18)] infant born from a mother with r(18) mosaicism

Introducción. La alteración autosómica por una formación en anillo del cromosoma 18 es una aberración poco frecuente que se encuentra en relación con malformaciones fenotípicas, aunadas a problemas neurológicos, anormalidades óseas en extremidades y deficiencia de hormona de crecimiento. Caso clínico. Se presenta un paciente masculino de 3 meses de edad con dismorfias craneofaciales treboliformes con suturas cerradas, frente amplia ovoide, comisuras palpebrales pequeñas y ambigüedad de genitales, extremidades con manos pequeñas, dedos sobrepuestos, pies pequeños, ortejos con sindactilia bilateral. El paciente presentó 2 líneas celulares, con una fórmula cromosómica en mosaico 46,XY/46,XY, r(18). La madre del paciente tiene también mosaico para el cromosoma en anillo. Conclusión. Dentro de las alteraciones cromosómicas, el anillo del cromosoma autosómico número 18 es rara, las principales alteraciones fenotípicas en este estudio estuvieron relacionadas con el desarrollo neurológico, genital y de las extremidades

Asoción del síndrome de Wolf-Hirschhorn (deleción del brazo corto del cromosoma 4) con el síndrome de rubéola congénita / Association of the Wolf-Hirschhorn syndrome (deletion of the short arm at chromosome 4) with congenital rubella

Introducción. El síndrome de Wolf-Hirschhorn (SWH) es una cromosopatía poco frecuente, debido a la delección en la banda del brazo 4p16.3 que se manifiesta con una amplia variedad clínica, incluyendo malformaciones craneofaciales importantes. Caso clínico. Paciente de 3 mmeses de edad que acudió por presentar paladar hendido y que inició su manejo en el servicio de cirugía maxilofacial. Con el antecedente materno de haber presentado cuadro exantemático diagnósticado como rubéola durante el primer trimestre del embarazo. Se detectaron múltiples malformaciones congénitas agregadas (cardiovasculares, oftalmológicas y ortopédicas). Conclusiones. De acuerdo a los hallazgos fenotípicos se realizó el diagnóstico de SWH asociado a síndrome de rubéola congénita. Es éste el primer reporte en que se documenta la asociación de ambos síndromes

Síndrome de Cockayne: informe de seis pacientes en dos familias mexicanas / Cockayne syndrome: six cases report in two mexican families

Introducción. Se presentan 6 casos de síndrome de Cockayne provenientes de 2 familias viviendo en una pequeña población donde existe un incremento en el grado de consanguinidad. Presentación de los casos clínicos. Las manifestaciones clínicas propias del síndrome fueron corroboradas en el Hospital para el Niño Poblano en forma multidisciplinaria encontrándose principalmente: alteraciones dermatológicas como sensibilidad a la luz solar y predisposición a cáncer de piel "xeroderma pigmentoso"; endocrinilógicas como talla baja, y apariencia senil; oculares desde cataratas hasta degeneración pigmentaria de la retina; problemas neurológicos con retardo mental leve y grave; pérdida de la audición; así como alteraciones óseas degenerativas de miembros inferiores; superiores y columna vertebral. Conslusiones. Se diagnostican 6 casos de síndrome de Cockayne en 2 familias mexicanas consanguíneas provenientes de una zona con un alto grado de consanguinidad

Cistinosis: informe de un caso / Cystinosis: a case report

Se presenta el caso de un niño de dos años de edad cistinosis clásica, manifestada por síndrome de Fanconi (glucosuria, aminoaciduria y fosfaturia), raquitismo, talla baja, presencia de cristales de cistina en córnea y daño glomerular progresivo; demostrándose en le biopsia renal por medio de microscopia electrónica el acúmulo de los característicos cristales hexagonales de cistina. Debido a que la frecuencia de esta patología en nuestro país es muy baja, y el cuadro clínico de nuestro paciente es representativo de la variante infantil nefropática, decidimos realizar este informe